Latest Teva Pharmaceutical Industries Ltd (TEVA) H
Post# of 116
Posted On: 03/13/2014 2:44:57 PM
Latest Teva Pharmaceutical Industries Ltd (TEVA) Headlines
Unfavorable Ruling for Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 54 mins ago
The court found Pfizer's reissue patent for Celebrex to be invalid.
Teva Hosts UK and Israeli Prime Ministers at UK-Israel Innovation Event - Announce Collaboration on New National Clinical Drug Development Initiative and Dementia Research
Business Wire - Thu Mar 13, 10:14AM CDT
--The initiative creates a single point of entry into the UK health system reducing complexity and increasing speed, efficiency of running drug development programs
Shares of TEVA Up 21.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 13, 9:35AM CDT
SmarTrend identified an Uptrend for Teva Pharmaceutical Industries (NASDAQ:TEVA) on November 20th, 2013 at $40.26. In approximately 4 months, Teva Pharmaceutical Industries has returned 21.53% as of today's recent price of $48.93.
2014 Hormone Replacement Therapy Global Strategic Business Report - IMS Consensus Guidelines Paving Way for More Clarity of HRT
M2 - Thu Mar 13, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/657h9p/hormone) has announced the addition of the "Hormone Replacement Therapy (HRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Hormone Replacement Therapy (HRT) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. MARKET TRENDS & ISSUES 4. COMPETITIVE LANDSCAPE 5. THERAPY PROFILE - A REVIEW OF SELECT RECENT STUDIES CONDUCTED - Researchers at Yale University Discover Discontinuation HRT May Lead to Premature Deaths - Bioidenticals versus Synthetic Hormone Replacement Therapy Agents - Studies at University of Sydney Researchers Reveal the Safety of Short-Term Unopposed Estrogens - US Researchers Reveal HRT Risks May be Dependent on Weight and Other Factors - Studies Prove HRT to Lower Risk of Pancreatic Cancer - University of Texas Reveal HRT Linked to Risks of Kidney Stones - Researchers at the Sundsvall Hospital Demonstrate Increased Incidence of Cataract Development in Women Undergoing HRT - Researchers at University of Southern California Demonstrate Estrogen Replacement Therapies Lower Stress Levels in Older Women - Studies at Uppsala University Hospital Demonstrate HRT is Associated with Improved Muscle Functioning in Postmenopausal women - Finnish Study Reveals HRT Usage Assist in the Treatment of Hot Flashes in Post Menopausal Women - Researchers at Johns Hopkins University Demonstrate Women Undergoing Hormone Therapy Less Prone to Alzheimer's Disease - French Study Reveals Hormone Replacement Pills May Affect Gall Bladder - Danish Studies Proves HRT Lowers Risk of Heart Attack and Heart Failure 6. PRODUCT OVERVIEW 7. PRODUCT INTRODUCTIONS/APPROVALS - Pfizer Receives FDA Approval for DUAVEE for Treatment of Vasomotor Symptoms - Noven Pharmaceuticals Launches Brisdelle Capsules - Lawley Pharmaceuticals Launches Profeme progesterone Bioidentical Hormone Replacement Cream - Bayer Receives FDA Approval for Low-Dose ANGELIQ? Tablets - Noven Pharmaceuticals Receives USFDA Approval for Minivelle - Mylan Pharmaceuticals Introduces Letrozole Tablets - Novo Nordisk Unveils Vagifem? 10?g - Amgen Obtains FDA Approval for Prolia in Treating Postmenopausal Women at Greater Risk of Osteoporosis 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. EUROPE 4. ASIA-PACIFIC 5. LATIN AMERICA 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 40 companies including many key and niche players such as: - Abbott Laboratories - AbbVie - Actavis - Bayer Pharma - Bayer Pharma's Hormone Replacement Therapy Product Pipeline - Hisamitsu Pharmaceutical - Noven Pharmaceuticals - Merck Sharp & Dohme - Novartis - Novo Nordisk - Orion - Pfizer - Rottapharm Madaus - Teva Pharmaceutical Industries - TherapeuticsMD - Upsher-Smith Laboratories For more information visit http://www.researchandmarkets.com/research/657h9p/hormone About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Pfizer Loses Patent On Celebrex, Plans To Appeal
at Investor's Business Daily - Wed Mar 12, 2:59PM CDT
Big pharma Pfizer (PFE) briefly halted trading Wednesday afternoon to announce that a patent on best-selling arthritis drug Celebrex had been invalidated by a district court. When trading resumed, shares were down nearly 1% in the stock market today....
Narrower-than-Expected Loss at OncoGenex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 12:34PM CDT
OncoGenex Pharma reported a loss of 45 cents per share in the 4Q13, narrower than the Zacks Consensus Estimate of a loss of 62 cents.
Will Horizon Pharma Spike Again On Quarterly Report?
at Investor's Business Daily - Wed Mar 12, 7:02AM CDT
Shares of small specialty drug company Horizon Pharma (HZNP) have been on the move since it reported third-quarter results in early November, thanks to expectations for the firm's novel drugs that treat arthritis, pain and inflammatory conditions....
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2013
CNW Group - Tue Mar 11, 3:00PM CDT
Conference call to be held on Tuesday, March 11, 2014 at 4:30 p.m. Eastern Time
Teva Pharmaceuticals and Volunteers in Medicine Partner to Expand Access to Healthcare in the U.S.
Business Wire - Mon Mar 10, 10:02AM CDT
Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Volunteers in Medicine (VIM), a national nonprofit organization dedicated to helping communities provide free primary healthcare clinics for families and individuals, today announced their 2014 National Partnership to make healthcare services more readily available to the uninsured.
Investigation Report on China's Quetiapine Market to 2018 - A Drug for Schizophrenia Originally by Astra Zeneca
M2 - Mon Mar 10, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/42f3t2/investigation) has announced the addition of the "Investigation Report on China Quetiapine Market, 2009-2018" report to their offering. Statistics shows that the number of schizophrene in China has exceeded 10 million by the end of 2013, and it is still rising year after year. Quetiapine is originally developed by Astra Zeneca and has curative effect on various schizophrenic symptoms. It was firstly approved to the U.K. market in July 1997 and to the U.S. market on September 26, 1997 by FDA with the trade name ""Seroquel"". Patent of this product expired on March 26, 2012. To prolong its life cycle, long-acting release formulation of quetiapine developed by Astra Zeneca was approved to the U.S. market on May 17, 2007 with the trade name ""Seroquel XR"", which extends its patent protection to November 28, 2017. After that it has come into markets of several countries sequentially, such as Germany and China. In 2012, global sales revenue of Seroquel and Seroquel XR was USD 2,803 million, of which the former dropped by 70% to USD 1,294 million while the later increased to USD 1,509 million. The moment the patent of Seroquel expired, it became target of many generic drug manufacturers. On March 22, 2012, the U.K. High Court ruled that the patent of Seroquel XR prescription was invalid. However, District Court of New Jersey later ruled that patent of Seroquel XR was valid. Consequently, the production of Seroquel generic drug by Anchen, Osmotica, Torrent and Mylan Pharmaceutical Company has violated the patent of Seroquel XR prescription, which expires in 2017. On March 27, 2012, Teva Pharmaceutical Industries Limited launched generic drugs of Seroquel and Seroquel XL in the U.K. on the same day, Dr. Reddy's Lab from India launched Seroquel generic drug in the U.S. Astra Zeneca permitted Intelli to sell generic drug of Seroquel XL from November 2016. Quetiapine produced by Astra Zeneca was approved to China in 2000 with the trade name ""Seroquel"". In the same year, Hunan Dongting Pharmaceutical Co., Ltd. became the first approved manufacturer to produce quetiapine raw material and troche with the brand name ""Qi Wei"". In 2003, Suzhou Pharmaceutical Group Co., Ltd. was also approved to produce quetiapine raw material and troche with the brand name ""Shu Si"". Moreover, Chongqing Fuan Pharmaceutical Co., Ltd. and Zhejiang Supor Pharmaceuticals Co., Ltd. received raw material approvals respectively in 2011 and 2012. Many pharmaceutical manufacturers in China have reported quetiapine tablet production, among which Suzhou Pharmaceutical Group Co., Ltd. reported the production of quetiapine sustained-release tablets in 2012. Key Topics Covered: 1 Relevant Concepts of Quetiapine 2 Market Overview of Quetiapine in China 3 Investigation on Sales Value of Quetiapine in China, 2009-2013 4 Investigation on Market Share of Major Quetiapine Manufacturers in China, 2009-2013 5 Investigation on Market Size of Quetiapine by Dosage Form in China, 2009-2013 6 Reference Price of Quetiapine Produced by Different Enterprises in China Hospital Market, 2014 7 Analysis on Major Quetiapine Manufacturers in China, 2009-2014 8 Prospect of China Quetiapine Market, 2014-2018 For more information visit http://www.researchandmarkets.com/research/42...estigation
Teva Pharmaceutical Industries reports availibility of generic Xeloda Tablets 150 MG and 500 MG in the US
M2 - Mon Mar 10, 4:06AM CDT
Pharmaceutical company Teva Pharmaceutical Industries (NYSE:TEVA) stated on Friday that it has unveiled the generic Xeloda (Capecitabine) Tablets, 150 MG and 500 MG, in the US market.
South Carolina's Suit to Recover Millions From Drug Company to Move Forward, says Janet, Jenner & Suggs, LLC
PR Newswire - Fri Mar 07, 5:03PM CST
The South Carolina Court of Common Pleas, Fifth Judicial Circuit has issued a ruling that will allow the State of South Carolina to move forward with efforts to hold pharmaceutical giant, Cephalon, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., accountable for overpayments by the State Health Plan and for violations of the South Carolina Unfair Trade Practices Act.
Teva Announces Launch of Generic Xeloda(R) Tablets 150 MG and 500 MG in the United States
Business Wire - Fri Mar 07, 11:15AM CST
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces the launch of the generic equivalent to Xeloda(R) (Capecitabine) Tablets, 150 MG and 500 MG, in the United States. Xeloda(R) is marketed by Genentech in the United States. Teva was the first to receive approval on its ANDA from the U.S. Food and Drug Administration on September 16, 2013 and is launching today per a settlement agreement.
Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
at The Street - Fri Mar 07, 9:49AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Today's Analysis - Stocks Hitting New Highs: Brocade Communications Systems, Huntsman, Kroger, and Teva Pharma Industries
PR Newswire - Fri Mar 07, 7:00AM CST
On Thursday, March 06, 2014, the NASDAQ Composite finished at 4,352.13, down 0.13% for the day. The Dow Jones Industrial Average closed the session at 16,421.89, up 0.38% and the S&P 500 ended the day at 1,877.03, higher by 0.17%. The gains were broad based with 7 of 10 sectors going up. Investor-Edge.com looks at some of the equities that during the last session hit a new 52-week high. These include Brocade Communications Systems Inc.(NASDAQ:BRCD), Huntsman Corporation (NYSE:HUN), The Kroger Company (NYSE:KR), and Teva Pharmaceutical Industries Ltd (NYSE:TEVA). Free research on these five companies can be accessed at:
Teva upgraded on drug launch
at Investor's Business Daily - Thu Mar 06, 5:39PM CST
The generic-drug maker was upgraded to outperform by Leerink Partners on the rise of its multiple-sclerosis drug. According to the analyst's survey, 40% of users are estimated to switch to Teva Pharmaceutical's (TEVA) new 40-milligram, thrice-weekly...
Teva Upgraded On Strong Launch Of Next-Gen Copaxone
at Investor's Business Daily - Thu Mar 06, 11:03AM CST
Leerink Partners upgraded Teva Pharmaceutical Industries (TEVA) to outperform Thursday, sending the stock up to a three-year high on the stock market today. Analyst Jason Gerberry wrote that his survey of the multiple-sclerosis market showed strong...
Upgrade Alert for Teva Pharmaceutical Industries (TEVA)
Comtex SmarTrend(R) - Thu Mar 06, 7:57AM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) was upgraded from Market Perform to Outperform at Leerink today. The stock closed yesterday at $49.80 on volume of 7.9 million shares, above average daily volume of 7.5 million. Teva Pharmaceutical Industries (NASDAQ:TEVA) is currently priced 6.1% above its average consensus analyst price target of $46.76. The stock should discover initial support at its 50-day moving average (MA) of $44.11 and subsequent support at its 200-day MA of $40.39.
Safeguard Scientifics Announces Fourth Quarter and Full-Year 2013 Financial Results
Business Wire - Thu Mar 06, 5:00AM CST
--Company Increases Share Repurchase Program;
Unfavorable Ruling for Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 54 mins ago
The court found Pfizer's reissue patent for Celebrex to be invalid.
Teva Hosts UK and Israeli Prime Ministers at UK-Israel Innovation Event - Announce Collaboration on New National Clinical Drug Development Initiative and Dementia Research
Business Wire - Thu Mar 13, 10:14AM CDT
--The initiative creates a single point of entry into the UK health system reducing complexity and increasing speed, efficiency of running drug development programs
Shares of TEVA Up 21.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 13, 9:35AM CDT
SmarTrend identified an Uptrend for Teva Pharmaceutical Industries (NASDAQ:TEVA) on November 20th, 2013 at $40.26. In approximately 4 months, Teva Pharmaceutical Industries has returned 21.53% as of today's recent price of $48.93.
2014 Hormone Replacement Therapy Global Strategic Business Report - IMS Consensus Guidelines Paving Way for More Clarity of HRT
M2 - Thu Mar 13, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/657h9p/hormone) has announced the addition of the "Hormone Replacement Therapy (HRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Hormone Replacement Therapy (HRT) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. MARKET TRENDS & ISSUES 4. COMPETITIVE LANDSCAPE 5. THERAPY PROFILE - A REVIEW OF SELECT RECENT STUDIES CONDUCTED - Researchers at Yale University Discover Discontinuation HRT May Lead to Premature Deaths - Bioidenticals versus Synthetic Hormone Replacement Therapy Agents - Studies at University of Sydney Researchers Reveal the Safety of Short-Term Unopposed Estrogens - US Researchers Reveal HRT Risks May be Dependent on Weight and Other Factors - Studies Prove HRT to Lower Risk of Pancreatic Cancer - University of Texas Reveal HRT Linked to Risks of Kidney Stones - Researchers at the Sundsvall Hospital Demonstrate Increased Incidence of Cataract Development in Women Undergoing HRT - Researchers at University of Southern California Demonstrate Estrogen Replacement Therapies Lower Stress Levels in Older Women - Studies at Uppsala University Hospital Demonstrate HRT is Associated with Improved Muscle Functioning in Postmenopausal women - Finnish Study Reveals HRT Usage Assist in the Treatment of Hot Flashes in Post Menopausal Women - Researchers at Johns Hopkins University Demonstrate Women Undergoing Hormone Therapy Less Prone to Alzheimer's Disease - French Study Reveals Hormone Replacement Pills May Affect Gall Bladder - Danish Studies Proves HRT Lowers Risk of Heart Attack and Heart Failure 6. PRODUCT OVERVIEW 7. PRODUCT INTRODUCTIONS/APPROVALS - Pfizer Receives FDA Approval for DUAVEE for Treatment of Vasomotor Symptoms - Noven Pharmaceuticals Launches Brisdelle Capsules - Lawley Pharmaceuticals Launches Profeme progesterone Bioidentical Hormone Replacement Cream - Bayer Receives FDA Approval for Low-Dose ANGELIQ? Tablets - Noven Pharmaceuticals Receives USFDA Approval for Minivelle - Mylan Pharmaceuticals Introduces Letrozole Tablets - Novo Nordisk Unveils Vagifem? 10?g - Amgen Obtains FDA Approval for Prolia in Treating Postmenopausal Women at Greater Risk of Osteoporosis 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. EUROPE 4. ASIA-PACIFIC 5. LATIN AMERICA 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 40 companies including many key and niche players such as: - Abbott Laboratories - AbbVie - Actavis - Bayer Pharma - Bayer Pharma's Hormone Replacement Therapy Product Pipeline - Hisamitsu Pharmaceutical - Noven Pharmaceuticals - Merck Sharp & Dohme - Novartis - Novo Nordisk - Orion - Pfizer - Rottapharm Madaus - Teva Pharmaceutical Industries - TherapeuticsMD - Upsher-Smith Laboratories For more information visit http://www.researchandmarkets.com/research/657h9p/hormone About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Pfizer Loses Patent On Celebrex, Plans To Appeal
at Investor's Business Daily - Wed Mar 12, 2:59PM CDT
Big pharma Pfizer (PFE) briefly halted trading Wednesday afternoon to announce that a patent on best-selling arthritis drug Celebrex had been invalidated by a district court. When trading resumed, shares were down nearly 1% in the stock market today....
Narrower-than-Expected Loss at OncoGenex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 12:34PM CDT
OncoGenex Pharma reported a loss of 45 cents per share in the 4Q13, narrower than the Zacks Consensus Estimate of a loss of 62 cents.
Will Horizon Pharma Spike Again On Quarterly Report?
at Investor's Business Daily - Wed Mar 12, 7:02AM CDT
Shares of small specialty drug company Horizon Pharma (HZNP) have been on the move since it reported third-quarter results in early November, thanks to expectations for the firm's novel drugs that treat arthritis, pain and inflammatory conditions....
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2013
CNW Group - Tue Mar 11, 3:00PM CDT
Conference call to be held on Tuesday, March 11, 2014 at 4:30 p.m. Eastern Time
Teva Pharmaceuticals and Volunteers in Medicine Partner to Expand Access to Healthcare in the U.S.
Business Wire - Mon Mar 10, 10:02AM CDT
Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Volunteers in Medicine (VIM), a national nonprofit organization dedicated to helping communities provide free primary healthcare clinics for families and individuals, today announced their 2014 National Partnership to make healthcare services more readily available to the uninsured.
Investigation Report on China's Quetiapine Market to 2018 - A Drug for Schizophrenia Originally by Astra Zeneca
M2 - Mon Mar 10, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/42f3t2/investigation) has announced the addition of the "Investigation Report on China Quetiapine Market, 2009-2018" report to their offering. Statistics shows that the number of schizophrene in China has exceeded 10 million by the end of 2013, and it is still rising year after year. Quetiapine is originally developed by Astra Zeneca and has curative effect on various schizophrenic symptoms. It was firstly approved to the U.K. market in July 1997 and to the U.S. market on September 26, 1997 by FDA with the trade name ""Seroquel"". Patent of this product expired on March 26, 2012. To prolong its life cycle, long-acting release formulation of quetiapine developed by Astra Zeneca was approved to the U.S. market on May 17, 2007 with the trade name ""Seroquel XR"", which extends its patent protection to November 28, 2017. After that it has come into markets of several countries sequentially, such as Germany and China. In 2012, global sales revenue of Seroquel and Seroquel XR was USD 2,803 million, of which the former dropped by 70% to USD 1,294 million while the later increased to USD 1,509 million. The moment the patent of Seroquel expired, it became target of many generic drug manufacturers. On March 22, 2012, the U.K. High Court ruled that the patent of Seroquel XR prescription was invalid. However, District Court of New Jersey later ruled that patent of Seroquel XR was valid. Consequently, the production of Seroquel generic drug by Anchen, Osmotica, Torrent and Mylan Pharmaceutical Company has violated the patent of Seroquel XR prescription, which expires in 2017. On March 27, 2012, Teva Pharmaceutical Industries Limited launched generic drugs of Seroquel and Seroquel XL in the U.K. on the same day, Dr. Reddy's Lab from India launched Seroquel generic drug in the U.S. Astra Zeneca permitted Intelli to sell generic drug of Seroquel XL from November 2016. Quetiapine produced by Astra Zeneca was approved to China in 2000 with the trade name ""Seroquel"". In the same year, Hunan Dongting Pharmaceutical Co., Ltd. became the first approved manufacturer to produce quetiapine raw material and troche with the brand name ""Qi Wei"". In 2003, Suzhou Pharmaceutical Group Co., Ltd. was also approved to produce quetiapine raw material and troche with the brand name ""Shu Si"". Moreover, Chongqing Fuan Pharmaceutical Co., Ltd. and Zhejiang Supor Pharmaceuticals Co., Ltd. received raw material approvals respectively in 2011 and 2012. Many pharmaceutical manufacturers in China have reported quetiapine tablet production, among which Suzhou Pharmaceutical Group Co., Ltd. reported the production of quetiapine sustained-release tablets in 2012. Key Topics Covered: 1 Relevant Concepts of Quetiapine 2 Market Overview of Quetiapine in China 3 Investigation on Sales Value of Quetiapine in China, 2009-2013 4 Investigation on Market Share of Major Quetiapine Manufacturers in China, 2009-2013 5 Investigation on Market Size of Quetiapine by Dosage Form in China, 2009-2013 6 Reference Price of Quetiapine Produced by Different Enterprises in China Hospital Market, 2014 7 Analysis on Major Quetiapine Manufacturers in China, 2009-2014 8 Prospect of China Quetiapine Market, 2014-2018 For more information visit http://www.researchandmarkets.com/research/42...estigation
Teva Pharmaceutical Industries reports availibility of generic Xeloda Tablets 150 MG and 500 MG in the US
M2 - Mon Mar 10, 4:06AM CDT
Pharmaceutical company Teva Pharmaceutical Industries (NYSE:TEVA) stated on Friday that it has unveiled the generic Xeloda (Capecitabine) Tablets, 150 MG and 500 MG, in the US market.
South Carolina's Suit to Recover Millions From Drug Company to Move Forward, says Janet, Jenner & Suggs, LLC
PR Newswire - Fri Mar 07, 5:03PM CST
The South Carolina Court of Common Pleas, Fifth Judicial Circuit has issued a ruling that will allow the State of South Carolina to move forward with efforts to hold pharmaceutical giant, Cephalon, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., accountable for overpayments by the State Health Plan and for violations of the South Carolina Unfair Trade Practices Act.
Teva Announces Launch of Generic Xeloda(R) Tablets 150 MG and 500 MG in the United States
Business Wire - Fri Mar 07, 11:15AM CST
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces the launch of the generic equivalent to Xeloda(R) (Capecitabine) Tablets, 150 MG and 500 MG, in the United States. Xeloda(R) is marketed by Genentech in the United States. Teva was the first to receive approval on its ANDA from the U.S. Food and Drug Administration on September 16, 2013 and is launching today per a settlement agreement.
Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
at The Street - Fri Mar 07, 9:49AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Today's Analysis - Stocks Hitting New Highs: Brocade Communications Systems, Huntsman, Kroger, and Teva Pharma Industries
PR Newswire - Fri Mar 07, 7:00AM CST
On Thursday, March 06, 2014, the NASDAQ Composite finished at 4,352.13, down 0.13% for the day. The Dow Jones Industrial Average closed the session at 16,421.89, up 0.38% and the S&P 500 ended the day at 1,877.03, higher by 0.17%. The gains were broad based with 7 of 10 sectors going up. Investor-Edge.com looks at some of the equities that during the last session hit a new 52-week high. These include Brocade Communications Systems Inc.(NASDAQ:BRCD), Huntsman Corporation (NYSE:HUN), The Kroger Company (NYSE:KR), and Teva Pharmaceutical Industries Ltd (NYSE:TEVA). Free research on these five companies can be accessed at:
Teva upgraded on drug launch
at Investor's Business Daily - Thu Mar 06, 5:39PM CST
The generic-drug maker was upgraded to outperform by Leerink Partners on the rise of its multiple-sclerosis drug. According to the analyst's survey, 40% of users are estimated to switch to Teva Pharmaceutical's (TEVA) new 40-milligram, thrice-weekly...
Teva Upgraded On Strong Launch Of Next-Gen Copaxone
at Investor's Business Daily - Thu Mar 06, 11:03AM CST
Leerink Partners upgraded Teva Pharmaceutical Industries (TEVA) to outperform Thursday, sending the stock up to a three-year high on the stock market today. Analyst Jason Gerberry wrote that his survey of the multiple-sclerosis market showed strong...
Upgrade Alert for Teva Pharmaceutical Industries (TEVA)
Comtex SmarTrend(R) - Thu Mar 06, 7:57AM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) was upgraded from Market Perform to Outperform at Leerink today. The stock closed yesterday at $49.80 on volume of 7.9 million shares, above average daily volume of 7.5 million. Teva Pharmaceutical Industries (NASDAQ:TEVA) is currently priced 6.1% above its average consensus analyst price target of $46.76. The stock should discover initial support at its 50-day moving average (MA) of $44.11 and subsequent support at its 200-day MA of $40.39.
Safeguard Scientifics Announces Fourth Quarter and Full-Year 2013 Financial Results
Business Wire - Thu Mar 06, 5:00AM CST
--Company Increases Share Repurchase Program;
(0)
(0)Teva Pharmaceutical Industries Limited (TEVA) Stock Research Links
Scroll down for more posts ▼